• EE713 Cost-of-Illness of Generalized Pustular Psoriasis in Italy

    Dec 1, 2023, 00:00
  • HTA232 A Multi-Criteria Decision Analysis Framework for the Value Assessment of First-Line Treatment of Adult Patients with Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00
  • CO35 Clinical Outcomes Associated with Sodium Zirconium Cyclosilicate for Treating Hyperkalaemia in Patients Receiving Haemodialysis

    Dec 1, 2023, 00:00
  • PT2 Comparing UK Value Sets and Mapping Functions for EQ-5D

    Dec 1, 2023, 00:00
  • EE109 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in France

    Dec 1, 2023, 00:00
  • EE501 Impact of Eptinezumab on Healthcare Resource Utilization in Patients with Migraine in the United States: A Retrospective Cohort Claims Database Study

    Dec 1, 2023, 00:00
  • HTA206 How Do the Stricter Pricing Regulations of the Statutory Health Insurance Financial Stabilization Act (GKV-FINSTG) Affect Reimbursement Prices of New Drugs in Germany?

    Dec 1, 2023, 00:00
  • HPR80 Examination of the Changes in the Turkish Pharmaceutical Market between 2007 and 2021

    Dec 1, 2023, 00:00
  • EPH257 Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data

    Dec 1, 2023, 00:00
  • CO139 Acalabrutinib (AKA) Versus Venetoclax With Obinutuzumab (VEN+OBI) in Patients With Untreated Chronic Lymphocytic Leukemia (CLL) and Unmutated IGHV Genes – Indirect Comparison

    Dec 1, 2023, 00:00
  • SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

    Dec 1, 2023, 00:00
  • EE753 Cost-Effectiveness Analysis of Fracture Prevention with 25-Hydroxyvitamin D (25(OH)D) Screening Among the Population over 65 Years Old in China

    Dec 1, 2023, 00:00
  • HPR109 What Drives Socially Acceptable Costs in Outcomes Based Agreements? a Survey Studying Gene Therapies

    Dec 1, 2023, 00:00
  • CO106 A Structured Expert Elicitation Exercise Conducted With UK Clinicians to Inform and Validate Inputs for a Cost-Effectiveness Analysis of FILSUVEZ® Gel (Birch Bark Extract) in Epidermolysis Bullosa

    Dec 1, 2023, 00:00
  • HTA36 Monitoring of the Long-Term Impact of the COVID-19 Pandemic on the Decision Process of the Italian Medicine Agency

    Dec 1, 2023, 00:00
  • CO109 A Targeted Review of Pharmacological Therapies for the Treatment of Chronic Spontaneous Urticaria

    Dec 1, 2023, 00:00
  • EE745 Cost- Effectiveness of Pneumococcal Vaccination for Adults Aged 60 Years and Older in Peru

    Dec 1, 2023, 00:00
  • EPH231 The Impact of COVID-19 on National Disease Dynamics: Population-Based Interrupted Time Series Study in South Korea

    Dec 1, 2023, 00:00
  • EE482 Economic Cost of Implementation of a Frailty Care Bundle to Reduce Risk of Hospital Associated Decline Among Older Patients

    Dec 1, 2023, 00:00
  • SA71 Real-World Treatment Patterns for Acute Lymphoblastic Leukemia Utilizing Claims Data

    Dec 1, 2023, 00:00
  • EPH229 Hospitalization Patterns and Costs of Primary Biliary Cholangitis (PBC) in Germany

    Dec 1, 2023, 00:00
  • HTA271 Shifting Landscape of Indirect Comparison Methodologies and Their Role in Informing NICE Decision-Making Processes

    Dec 1, 2023, 00:00
  • EE214 The Cost-Effectiveness of Abemaciclib Combined With Endocrine Therapy (ET) for the Treatment of Persons With HR+, HER2- Node Positive, Early Breast Cancer (EBC) at High Risk of Recurren A Spanish Healthcare Perspective

    Dec 1, 2023, 00:00
  • MSR118 Identifying Potential Long-COVID Patients Using Machine Learning: A German Claims Data Analysis

    Dec 1, 2023, 00:00
  • PCR53 To What Extent European Value-Based Pricing Methodologies Take Into Account Patient Perspectives and Broader Societal Benefits?

    Dec 1, 2023, 00:00
  • EE228 Cost to Society and Financial Toxicity Related to Personalized Oncology Treatment in Bulgaria

    Dec 1, 2023, 00:00
  • MSR13 Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC)

    Dec 1, 2023, 00:00
  • EE635 Medical Cost Trends for Diseases Associated with Bedridden Rural Residents in Japan

    Dec 1, 2023, 00:00
  • EE257 Real-World, Longitudinal, Retrospective Study of Healthcare Resource Utilization of Patients With Atopic Dermatitis Under the Public Health Insurance Plan of Quebec, Canada

    Dec 1, 2023, 00:00
  • PT12 Perceived Financial Burden and Quality of Life Among Patients with Cancer

    Dec 1, 2023, 00:00
  • PCR43 A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)

    Dec 1, 2023, 00:00
  • PCR88 Use of Patient-Reported Outcomes for Sickle-Cell Disease in Clinical Trials – Do They Match with Consensus-Based Core Outcomes Sets Recommendations?

    Dec 1, 2023, 00:00
  • EE698 A Systematic Literature Review of Economic Evaluations in Primary Biliary Cholangitis

    Dec 1, 2023, 00:00
  • MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain

    Dec 1, 2023, 00:00
  • EE647 Excess Healthcare Resource Use Among Subgroups With Anxiety and Depressive Symptoms in Hungary

    Dec 1, 2023, 00:00
  • HTA37 Assessing the Definition and Outcomes of Innovative Drugs by Health Technology Assessment Bodies in England, France, and Italy (Q1 2023)

    Dec 1, 2023, 00:00
  • EPH102 Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) Among Canadian Infants

    Dec 1, 2023, 00:00
  • RWD127 Systemic Treatment of Non-Melanoma Skin Cancers in Fran Real-World Analysis Using French Data from the National Hospitalization Database

    Dec 1, 2023, 00:00
  • EE50 What Is the Economic Impact of an Early Adoption of High Efficacy Treatments in Multiple Sclerosis? A Cost-Consequence Analysis From a Societal Perspective in the Portuguese Setting

    Dec 1, 2023, 00:00
  • EPH197 An Integrated Modelling Methodology for Estimating Global, Regional, and Country-Specific Incidence and Prevalence of Tay-Sachs Disease at the Subtype Level

    Dec 1, 2023, 00:00
  • RWD148 Using Linked Data: Agreement in Diagnosis for Patients with Asthma or Diabetes

    Dec 1, 2023, 00:00
  • EPH117 The Phollow Cohort: Real-World Therapeutic Adherence to Blood Glucose-Lowering Drugs (EXCLUDING INSULINS) in Portugal

    Dec 1, 2023, 00:00
  • PT46 Does Public Research Investment on Emerging Infectious Diseases Correspond to Disease Burden in China? A Cross-Sectional Study from 2009 to 2019

    Dec 1, 2023, 00:00
  • PCR104 Is It Worth the Risk? Challenges and Recommendations for Devising Attributes and Levels for Safety-Related Attributes in Patient Preference Studies

    Dec 1, 2023, 00:00
  • EE554 Cost-Effectiveness Analysis of Novoseven® Treatment for Postpartum Hemorrhage in Turkiye

    Dec 1, 2023, 00:00
  • EE358 A Systematic Literature Review of Reviews Related to the Impacts of Catastrophic Health Expenditures Related to Cancer Care

    Dec 1, 2023, 00:00
  • EPH39 Epidemiology and Patient Characteristics of Pemphigus Vulgaris in Italy Based on Administrative Database

    Dec 1, 2023, 00:00
  • EE161 Economic Burden Associated with Stroke: A Comparative Analysis of Post-Stroke Care Costs

    Dec 1, 2023, 00:00
  • MSR91 What Are Unmet Needs for the Use of Registries in Regulatory/HTA Decision-Making in Europe? A Survey-Based Approach From the More-EUROPA Project

    Dec 1, 2023, 00:00
  • EE154 Cost-Effectiveness of Transcatheter Aortic Valve Intervention (TAVI) as Compared with Surgical Aortic Valve Intervention (SAVR) in Swedish Low Risk Aortic Stenosis Patients: Evidence Using Swedeheart Registry Data (2018-2020)

    Dec 1, 2023, 00:00
  • HTA26 Portuguese Clinical Practice and Costs in the Treatment of Acid Sphingomyelinase Deficiency Disease

    Dec 1, 2023, 00:00
  • EE460 Intraarterial Thrombectomy for Acute Ischemic Stroke: Cost-Effective or Dominant across All Age Groups in Brazil

    Dec 1, 2023, 00:00
  • PCR50 The Adelphi Adherence Questionnaire (ADAQ©): Psychometric Validation of a New Patient Self-Report Measure of Medication Adherence Across Multiple Disease Areas

    Dec 1, 2023, 00:00
  • PCR236 Treatment Preferences Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in France, Germany, Italy, Japan, Spain, the United States, and the United Kingdom

    Dec 1, 2023, 00:00
  • EE201 Clinical and Economic Consequences of Epilepsy Treatment across Incremental Treatment Lines in Spain: A Real Life Database Analysis

    Dec 1, 2023, 00:00
  • HPR55 Reimbursement of High Priced One-Shot Treatments in Korea: KYMRIAH and ZOLGENSMA Case Study

    Dec 1, 2023, 00:00
  • EE128 Budget Impact of the Jada System for the Treatment of Patients with Abnormal Post-Partum Bleeding or Hemorrhage in the United States

    Dec 1, 2023, 00:00
  • MT49 Cost-Effectiveness Analysis of Farapulse™ Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation

    Dec 1, 2023, 00:00
  • EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis

    Dec 1, 2023, 00:00
  • PT1 A Comparison of the UK and Australian Interim Value Sets for the Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE)

    Dec 1, 2023, 00:00
  • EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-12/23 and IL-23 Inhibitors in the Treatment of Psoriatic Arthritis in Sweden

    Dec 1, 2023, 00:00
  • CO70 COPD Exacerbations Pre, During, and Post COVID-19 Pandemic in the US

    Dec 1, 2023, 00:00
  • EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States

    Dec 1, 2023, 00:00
  • EPH177 The Impact of COVID-19 on National Mortality: Population-Based Interrupted Time Series Study in South Korea

    Dec 1, 2023, 00:00
  • RWD173 Chronification in the Use of Benzodiacepines: Incidence Stratified by Sex and Age Groups

    Dec 1, 2023, 00:00
  • EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands

    Dec 1, 2023, 00:00
  • HPR122 A Conceptual Modeling Framework for Manufacturers to Navigate the Inflation Reduction Act and to Negotiate a “Fair Maximum Price”

    Dec 1, 2023, 00:00
  • PCR202 Atoderma: Clinical and Economic Burden of Moderate to Severe Atopic Dermatitis in the Czech Republic

    Dec 1, 2023, 00:00
  • EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland

    Dec 1, 2023, 00:00
  • P36 Towards a Collaborative Value Assessment Framework for Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Findings and Implications

    Dec 1, 2023, 00:00
  • OP3 Single-Use Vs Reusable Endoscopy Reprocessing: An Efficiency Survey of Nurses and Technicians

    Dec 1, 2023, 00:00
  • EE212 Understanding Service Use for Melanoma in the UK National Health Servi An Expert Elicitation Exercise Using a New Method for Eliciting Proportions

    Dec 1, 2023, 00:00
  • HTA141 Exploring the Role of Patient Experience Data and Patient Involvement in Health Technology Assessment Decision Making

    Dec 1, 2023, 00:00
  • PCR233 Socioeconomic Impact of Muscular Dystrophies on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2023, 00:00
  • PT7 Data Standardization in Brazil: An OMOP Common Data Model Approach in a DATASUS Cohort

    Dec 1, 2023, 00:00
  • MSR29 A Comparative Analysis of Missing Value Imputation Techniques: Parametric Imputation with eCDF (PIE) Vs Markov Chain Monte Carlo Imputation (MCMC)

    Dec 1, 2023, 00:00
  • MSR10 Incidence, Prevalence, and Clinical Characteristics of Patients with Chronic Lymphocytic Leukemia (CLL) in Spain: Natural Language Processing (NLP) Analysis of Electronic Health Records (EHRs)

    Dec 1, 2023, 00:00
  • HTA210 Characteristics and Outcomes of Health Technology Assessment Submissions for Advanced Therapy Medicinal Products in Europe: Perspective From Non-EU5 Countries

    Dec 1, 2023, 00:00
  • OP21 A Validated Dutch Translation of the CHEERS II Statement

    Dec 1, 2023, 00:00
  • HTA273 Managed Access Agreements in the UK: A Detailed Analysis of NICE's Utilization and Impact on Access

    Dec 1, 2023, 00:00
  • HPR73 Underfunding of Public Health System and Unmet Dental Needs Among the European Elderly Population

    Dec 1, 2023, 00:00
  • HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study

    Dec 1, 2023, 00:00
  • EPH94 Comparative Analysis of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Nationwide US Medicare Perspective

    Dec 1, 2023, 00:00
  • Faster Diagnosis and Treatment for Cancer: Assessing Patient Pathways Using a Panel Regression Analysis of the English National Cancer Registration Data [Editor's Choice]

    Dec 1, 2023, 00:00
  • EPH51 Artificial Intelligence (AI) Tools for Outbreak Detection and Response: A Transnational Platform for Surveillance, Monitoring and Decision Support

    Dec 1, 2023, 00:00
  • HTA323 Analyzing Historic Health Technology Assessments (HTAs): Surrogate Endpoints (SEs) in the Interstitial Pneumonia With Autoimmune Features (IPF)/Interstitial Lung Disease (ILD) Therapeutic Domain

    Dec 1, 2023, 00:00
  • HSD49 Impact of Endoscope Choice on Nurse Time in GI Surgical Procedures: A Prospective Study in a Danish University Hospital

    Dec 1, 2023, 00:00
  • HPR72 Regulation and Reality of the Market Access Process for Digital Health Applications (DiGA) in Germany

    Dec 1, 2023, 00:00
  • EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico

    Dec 1, 2023, 00:00
  • EE247 Emicizumab is Cost-Saving for Finnish Hemophilia A Patients with Factor VIII Inhibitors

    Dec 1, 2023, 00:00
  • PCR222 Safety and Quality of Life of Various Artificial Pancreas Systems in Patients With Type 1 Diabetes Mellitus: A Systematic Review of Real-World Evidence

    Dec 1, 2023, 00:00
  • HTA164 Implementing Combination Treatment Cost-Effectiveness Solutions Beyond the Legal Challenges – What Else Needs to be in Place?

    Dec 1, 2023, 00:00
  • HPR127 Corporate Social Responsibility in Health Technology Industry, in Greece

    Dec 1, 2023, 00:00
  • SA70 Clinical Benefits and Cost-Effectiveness of High-Dose Capsaicin Cutaneous Patches for Peripheral Neuropathic Pain: A Literature Review

    Dec 1, 2023, 00:00
  • EE590 Assessing Health Outcomes and Cost-Effectiveness of Adult HPV Vaccination in Italy

    Dec 1, 2023, 00:00
  • EE686 Cost Effectiveness of Ruxolitinib for Treatment of Steroid Refractory Acute Graft Versus Host Disease in Patients >12 Years of Age from a Singapore Healthcare System Perspective

    Dec 1, 2023, 00:00
  • EE493 Healthcare Resource Utilization Associated with Major Depressive Disorder with Insomnia Symptoms: A Retrospective Cohort Study in Hungary

    Dec 1, 2023, 00:00
  • SA76 Systematic Literature Review on Economic Burden of Retinitis Pigmentosa (RP) and Visual Impairment in France

    Dec 1, 2023, 00:00
  • EE661 The Quality of Economic Evaluations of Breast Cancer for Diagnostics, Screening, and Therapeutics in the Middle East: A Targeted Literature Review

    Dec 1, 2023, 00:00
  • SA80 Priors on Between-Study Heterogeneity in Bayesian Meta-Analysis Models: A Simulation Study Using Hamiltonian Monte Carlo Sampling

    Dec 1, 2023, 00:00
  • RWD75 An Innovative Data Collection System for Improving Outcomes in Patients Treated with Diabetes Technology

    Dec 1, 2023, 00:00
  • EE569 Cost-Effectiveness of Eftrenonacog Alfa in Treatment of Severe Haemophilia B Patients in Turkey

    Dec 1, 2023, 00:00
  • PT48 International Reference Pricing Analysis of Medicines in Turkiye By 2022

    Dec 1, 2023, 00:00
  • EE540 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in the United Kingdom

    Dec 1, 2023, 00:00
  • HSD119 Patient Pathways, Genetic Testing, and Diagnosis of X-Linked Retinitis Pigmentosa in Europe: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey

    Dec 1, 2023, 00:00
  • SA41 Novel Method for Indirect Comparison of Treatment Sequences Using Averaged Parametric Survival Models with Application to Hepatocellular Carcinoma

    Dec 1, 2023, 00:00
  • EE469 Diabetic Retinopathy in Algeria: Costs Estimation and Medical-Economic Value of Automated Methods AI-Based in Early Screening

    Dec 1, 2023, 00:00
  • HPR10 Added Benefit and Revenues of Oncology Drugs Approved By the European Medicines Agency between 1995 and 2020

    Dec 1, 2023, 00:00
  • RWD168 Epidemiology of Respiratory Syncytial Virus in Uppsala and Stockholm: A Population-Based Study

    Dec 1, 2023, 00:00
  • EE187 Use of Resources and Economic Cost of People Living with HIV in the Brazilian Supplementary Health System

    Dec 1, 2023, 00:00
  • EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis

    Dec 1, 2023, 00:00
  • EE423 The Cost Savings Potential Associated with the Use of Nefecon for Adults with Primary IgA Nephropathy in the United States

    Dec 1, 2023, 00:00
  • EE360 Clinical and Economic Evaluation of Atezolizumab Versus Durvalumab Administration in Adult Patients with Extensive Stage Small Cell Lung Cancer

    Dec 1, 2023, 00:00
  • PCR114 The Association Between Health-Related Quality of Life and Social Determinants of Health for Diabetes in Japan: A Cross-Sectional Patient Survey

    Dec 1, 2023, 00:00
  • MT70 Robotic-Assisted Surgery Versus Open Surgery in Endometrial Cancer: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • RWD159 Comparison of Livingstone's Estimates of Prevalence of Six Different Rare Blood Cancers with Darwin EU

    Dec 1, 2023, 00:00
  • HTA366 NICE Technology Appraisals Based on Single-Arm Trials in 2022 – What Can We Learn from Them?

    Dec 1, 2023, 00:00
  • EE319 Update to the Macrovascular Submodels of the IQVIA Core Diabetes Model

    Dec 1, 2023, 00:00
  • PCR176 Establishing the Interchangeability Between CSF and PET to Identify Patients With Alzheimer's Disease Pathology

    Dec 1, 2023, 00:00
  • HSD52 Employess Satisfaction Level from Working Conditions at the Public Psychiatric Hospital of Athens, Greece

    Dec 1, 2023, 00:00
  • HPR219 "Direct Access" Experiment in Fran Potential Impact on the Pricing of Innovative Medicines

    Dec 1, 2023, 00:00
  • EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden

    Dec 1, 2023, 00:00
  • HTA35 G-BA Vs. InEK: Navigating Divergent Requirements Between the Two Key Bodies Behind Inpatient Drug Reimbursement in Germany

    Dec 1, 2023, 00:00
  • PCR248 Meaningful Within-Patient Change Threshold Range for the FACIT-Fatigue in Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Dec 1, 2023, 00:00
  • PCR115 Health-Related Quality of Life Associated With Common Stoma Complications—Peristomal Skin Complications and Leakages Onto Clothes

    Dec 1, 2023, 00:00
  • EE149 Surge Capacity for Preserving Accessibility to Primary Healthcare Services during the COVID19 Pandemic in a Middle Income Country

    Dec 1, 2023, 00:00
  • MSR102 Advancing Causal Inference With Machine Learning and Real-World Data: An Application of Targeted Machine Learning and Super Learners on Hospital-Acquired Pressure Injuries From MIMIC IV

    Dec 1, 2023, 00:00
  • PCR89 Predicting EQ-5D-5L Score by Using SGRQ in Patients with Asthma and/or COPD in NOVELTY

    Dec 1, 2023, 00:00
  • HPR71 All Back to Square One: What Follows from the New Algorithm for Drug Pricing in Germany?

    Dec 1, 2023, 00:00
  • HSD118 Patient Safety in Oncology: Quantifying the Hospital-Associated Risks with a Discrete-Events Simulation

    Dec 1, 2023, 00:00
  • EE64 Change in Healthcare Resource Use and Associated Costs of Patients with Metastatic Lung Cancer between 2013 and 2019: An Observational Study from the French National Claims Database

    Dec 1, 2023, 00:00
  • EE447 Working With Probabilistic Models for Cost-Effectiveness Analysis: Computational Tools Integrating Exact Methods vs Simulation-Based Approaches

    Dec 1, 2023, 00:00
  • EE588 The Budget Impact of Introducing Robotic-Assisted Surgery for Spinal Fusion Procedures in Spain

    Dec 1, 2023, 00:00
  • EE127 CAR-T Cell Therapies' Pathway: Evolution of Management and of Costing Methodology in the French Cost-Effectiveness Analyses (CEA) Landscape

    Dec 1, 2023, 00:00
  • EE416 The Cost-Effectiveness of WaveWriter Alpha Spinal Cord Stimulation System in a Swedish Setting

    Dec 1, 2023, 00:00
  • HTA332 Evaluating Transcatheter Valve Replacement in Tricuspid Regurgitation: Complexities and Limitations of Existing Models

    Dec 1, 2023, 00:00
  • MT3 Intracardiac Echocardiography Operational Experience of Chinese Interventional Cardiologists in Conducting Radio-Frequency Catheter Ablation for Cardiac Arrhythmias: A Cross-Sectional Survey Study

    Dec 1, 2023, 00:00
  • PCR6 Impact of Perianal Fistulas on Crohn’s Disease Patients

    Dec 1, 2023, 00:00
  • MSR64 How Is Machine Learning Being Used in HEOR? A Systematic Review of Trends and Methods

    Dec 1, 2023, 00:00
  • HTA70 The Italian Healthcare System Competences in View of the New European HTA Regulation

    Dec 1, 2023, 00:00
  • HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients in France

    Dec 1, 2023, 00:00
  • EE671 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Renal Cell Carcinoma Post-Nephrectomy in France

    Dec 1, 2023, 00:00
  • EE258 Healthcare Resource Utilization and Economic Burden of Hidradenitis Suppurativa in German Patients with Hidradenitis Suppurativa

    Dec 1, 2023, 00:00
  • HPR43 Are There Any Common Denominators for Early Access Programs in Europe?

    Dec 1, 2023, 00:00
  • CO45 A Systematic Review of Quality of Life and Gastroesophageal Reflux Disease

    Dec 1, 2023, 00:00
  • EE25 Cost-Effectiveness Analysis of S-Adenosylmethionine for the Treatment of Intrahepatic Cholestasis in China

    Dec 1, 2023, 00:00
  • EE283 Value of Information Analyses for Advanced Cell Therapies: A Systematic Review

    Dec 1, 2023, 00:00
  • EE531 Resource Optimization for Greek NHS Hospitals from the Use of Daratumumab SC for Multiple Myeloma

    Dec 1, 2023, 00:00
  • EE607 Development of an Online Database of Published Usable Mapping Algorithms Used to Estimate EQ-5D Utilities

    Dec 1, 2023, 00:00
  • EE259 The Societal Cost of Age-Related Macular Degeneration and Diabetic Macular Edema: An Estimation Using a Pragmatic Literature Review

    Dec 1, 2023, 00:00
  • CO144 A Trial-Based Health Utility Analysis in Patients with Acanthamoeba Keratitis

    Dec 1, 2023, 00:00
  • MT16 A Review of NICE Submissions for Medical Technologies in the UK: Key Trends over the Last 2 Years

    Dec 1, 2023, 00:00
  • HSD109 What Are the Main Challenges in Management Care of Stoma Patients in Fran Guidelines from Shield Multidisciplinary Experts for Optimization

    Dec 1, 2023, 00:00
  • EE510 Downstaging Pancreatic Cancer is Cost-Effective: Can We Achieve a Cost-Effective Early Diagnosis?

    Dec 1, 2023, 00:00
  • HTA207 Can We Speak to GPT to Inform Health Technology Assessments?

    Dec 1, 2023, 00:00
  • RWD162 Evolution of Breast Cancer Treatment Cost in the Last 36 Months: An Analysis From a Health Payer Perspective in Brazil

    Dec 1, 2023, 00:00
  • RWD85 A Systematic Literature Review on the Use of Real-World Evidence in NICE Technology Appraisals Indicated for Multiple Myeloma

    Dec 1, 2023, 00:00
  • EPH12 Estimating the Prevalence of Hepatitis Delta in the UK: A Migration Model Approach Applied in Practice

    Dec 1, 2023, 00:00
  • HTA136 Analysis of the Reimbursement and Pricing of Hybrid Medicines in France

    Dec 1, 2023, 00:00
  • PCR97 Impact of Paroxysmal Nocturnal Haemoglobinuria on Employment and Activity: Results from a Real-World Study

    Dec 1, 2023, 00:00
  • HTA77 Is Stedi Steady? an Exploration of the Uncertainties Underlying the Quantification of the Broader Value of Antibiotics

    Dec 1, 2023, 00:00
  • EE130 Impact of Phacoemulsification Equipment in Surgical Throughput, Under the Perspective of a Greek Hospital

    Dec 1, 2023, 00:00
  • MSR84 Summarizing Adverse Event Data in the Absence of High-Level Eviden The Case of Hearing Implants

    Dec 1, 2023, 00:00
  • HTA130 Different Approaches to the Health Economic Evaluations for the Health Technology Assessment Submissions

    Dec 1, 2023, 00:00
  • HPR78 From Submission to Reimbursement: Navigating the COVID-19 Ripple Effect on Therapy Access in Canada

    Dec 1, 2023, 00:00
  • EE407 Economic Assessment in Resource-Constrained Systems – a Case Study Using an Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema

    Dec 1, 2023, 00:00
  • HTA108 Willingness-to-Pay for Orphan Drugs – ICER Thresholds Approved by TLV in Sweden

    Dec 1, 2023, 00:00
  • EE575 Economic Analysis of the Costs Associated With Reusable Flexible Ureteroscopes – Implications for the Utilization of Single-Use Digital Flexible Ureteroscopes

    Dec 1, 2023, 00:00
  • RWD56 Real World Data for Planning a New Organised Cancer Screening Programme in the Czech Republic: Example of Prostate Cancer Screening

    Dec 1, 2023, 00:00
  • HPR66 Assessing the Impact and Strategic Implications of the HTA Regulation 2021/20282 on National Processes: A Scoping Review and Stakeholders Perspectives Through Semi-Structured Interviews

    Dec 1, 2023, 00:00
  • CO26 Efficacy of the Dupilumab 200 Mg Dose Every 2 Weeks in Children with Moderate-to-Severe Asthma during Voyage and Excursion

    Dec 1, 2023, 00:00
  • HSD56 Utilization of Vascular Assessment Before Lower Extremity Amputation Among Patients With Diabetic Foot Ulcerations in the US

    Dec 1, 2023, 00:00
  • PCR121 Insights, Needs, and Perspectives From Patients, Caregivers, and Healthcare Professionals on Shared Decision Making in Duchenne Muscular Dystrophy: A Qualitative Study

    Dec 1, 2023, 00:00
  • RWD104 Shifting Tides: Unveiling the Burden of Demographic Change in Germany Through Administrative Hospital Data

    Dec 1, 2023, 00:00
  • HPR33 Follow the Money: Reporting Public Contributions and Incentives on Research and Development Programs for Agenzia Italiana Del Farmaco (AIFA; ITALIAN MEDICINES AGENCY)

    Dec 1, 2023, 00:00
  • RWD134 Assessing the Association between Pain Burden and Limitations Among Older United States Adults with Pain who Used Opioids

    Dec 1, 2023, 00:00
  • PCR46 The Current Usage and Challenges of Goal Attainment Scaling in Clinical Settings

    Dec 1, 2023, 00:00
  • PT41 Real-World Evidence in Rare Diseases in Fran Treatment Patterns, Healthcare Resource Use, and Related Costs in Von Willebrand Disease (FORvWARD Study)

    Dec 1, 2023, 00:00
  • EE222 Cost Minimization Analysis of Damoctocog Alfa Pegol in the Treatment of Severe Hemophilia A Patients in Mexico

    Dec 1, 2023, 00:00
  • EE45 Differing Approaches to the Health Economic Investigation of the Informal Care of People Living With Multiple Sclerosis: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • PCR197 Quality of Life and Duchenne Muscular Dystrophy: Greek Translation of the Pediatric Quality of Life Inventory (PEDSQL)3.0 Duchenne Muscular Dystrophy Module

    Dec 1, 2023, 00:00
  • EE675 Cost-Effectiveness Analysis of Cancer Susceptibility Gene-Specific Prevention and Surveillance Strategies for Ovarian and Breast Cancer

    Dec 1, 2023, 00:00
  • CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Fran A Simulation Study

    Dec 1, 2023, 00:00
  • EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations

    Dec 1, 2023, 00:00
  • CO176 Treatment Approvals in Oncology and Relationship with Improvement in 5-Year Relative Survival for Cancer Patients in Europe

    Dec 1, 2023, 00:00
  • HSD18 Itch Intensity and Therapeutic Management of Pruritus in the Real-World Setting

    Dec 1, 2023, 00:00
  • EPH227 Clinical, Economic, and Patient-Reported Impact of Obesity in Selected European Countries: A Systematic Review

    Dec 1, 2023, 00:00
  • CO104 Identification and Selection of Biomarkers in Patient-Centric Treatment Management of Rare/Orphan Kidney Diseases: An Ongoing Research Project Aiming to Develop Personalized Treatment Algorithms

    Dec 1, 2023, 00:00
  • EE382 Burden and Economic Impact of Vaccine-Preventable Cancer Mortality in Europe

    Dec 1, 2023, 00:00
  • MSR54 COVID-19: Do All Patients Who Meet the EMA High-Risk Definition Receive Prescription?

    Dec 1, 2023, 00:00
  • EE593 Cost-Effectiveness Model of COVID-19 Vaccination: The United Kingdom Perspective

    Dec 1, 2023, 00:00
  • SA44 Clinical Burden of Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Focused Literature Review

    Dec 1, 2023, 00:00
  • MSR46 Breaking Through Limitations: Enhanced Systematic Literature Reviews With Large Language Models

    Dec 1, 2023, 00:00
  • HSD53 Effect of COVID-19 Pandemic on the Delivery Time and the Point of Re-Order of Pharmaceuticals at the Logistics Services in a Governmental Hospital in Riyadh Saudi Arabia

    Dec 1, 2023, 00:00
  • PCR110 Translation and Cultural Adaptation of Clinical Outcome Assessments (COAs)—Is Machine Translation a Viable Option?

    Dec 1, 2023, 00:00
  • HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland

    Dec 1, 2023, 00:00
  • EPH17 The Impact of COVID-19 Preventive Restrictions on the Development of Diseases of Despair: A Multi-Group Time Series Analysis

    Dec 1, 2023, 00:00
  • EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting

    Dec 1, 2023, 00:00
  • SA65 Trends in the Systematic Literature Reviews Over the Years

    Dec 1, 2023, 00:00
  • EE17 Societal Burden of Non-Alcoholic Steatohepatitis (NASH) in Denmark - Real-World Evidence from National Registries

    Dec 1, 2023, 00:00
  • HTA194 Do Health Technology Assessment (HTA) Bodies Recommend the Conduct and Submission of Artificial Intelligence-Based Literature Reviews (AILRS)?

    Dec 1, 2023, 00:00
  • EE427 Health Economic Decision Models Used in the Cost-Effectiveness Analyses of Innovative Products Submitted to the French National Authority for Health (HAS)

    Dec 1, 2023, 00:00
  • PCR159 Considerations for Maximizing the Research Value of PRO Data Collected in Clinical Care

    Dec 1, 2023, 00:00
  • EE454 What Is the Goal of Value-Based Pricing, and to Whom Is Value Created?

    Dec 1, 2023, 00:00
  • HTA101 Mapping Opportunities in the Access Landscape for a New Rare Disease Treatment Option in Multiple EU Countries

    Dec 1, 2023, 00:00
  • MSR23 EQ-5D-5L Valuation Studies: Do the Effects of Dimensional Health Problems Interact with Each Other?

    Dec 1, 2023, 00:00
  • HTA166 Cost-Effectiveness of Combination Pertuzumab+Trastuzumab Vs Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer (HER2+ eBC) in the Czech Republic

    Dec 1, 2023, 00:00
  • EE370 Cost-Effectiveness Analysis of Pembrolizumab as Adjuvant Treatment for Resected Stage IIB/IIC Melanoma in Greece

    Dec 1, 2023, 00:00
  • PCR109 Patient Associations’ Members’ Perceptions of Level and Importance of Participation in Health Technology Assessment in Greece

    Dec 1, 2023, 00:00
  • EE723 Budget Impact of New Potassium-Lowering Therapies in the Treatment of Chronic Hyperkalemia: A Saudi Experience

    Dec 1, 2023, 00:00
  • MT67 The Effectiveness of Body Composition Analysis Using Dual-Energy X-Ray Absorptiometry (DEXA) for Diagnosing Sarcopenia: Literature Review

    Dec 1, 2023, 00:00
  • PCR69 Understanding Determinants of the Burden Experienced by Informal Caregivers of Myasthenia Gravis Patients

    Dec 1, 2023, 00:00
  • HTA233 Transportability of Overall Survival Estimates from US to UK Populations Receiving First-Line Treatment for Advanced Non-Small-Cell Lung Cancer

    Dec 1, 2023, 00:00
  • MSR151 Causal Machine Learning for Assessing Pneumococcal Vaccine Effectiveness: Innovations in Real-World Data Analysis and Confounding Pathway Adjustment

    Dec 1, 2023, 00:00
  • HTA19 Insights Into NICE Technology Appraisal Outcomes in Oncology

    Dec 1, 2023, 00:00
  • MSR145 Identifying Effect of a Treatment from Observational Data in Absence of Contemporaneous Control: Example of the French Study Tosca, Comparing Cemiplimab Vs. Historical Systemic Treatment in Cutaneous Squamous Cell Carcinoma

    Dec 1, 2023, 00:00
  • HPR220 Assessment of the Relevance and Credibility of Indirect Treatment Comparisons (ITCs) to Help Inform Health Technology Assessment (HTA) and Reimbursement Decision-Making: Results of a 5-Country Payer Survey

    Dec 1, 2023, 00:00
  • EE13 Using Sensor-Based Glucose Monitors Dominates Self-Monitoring of Blood Glucose for Adults with Type 1 Diabetes in the Danish Healthcare Setting

    Dec 1, 2023, 00:00
  • EE210 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as Neoadjuvant Therapy and Continued as a Single Agent as Adjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer in Greece

    Dec 1, 2023, 00:00
  • RWD153 Economic and Humanistic Burden Among Patients With Non-Radiographic Axial Spondyloarthritis in China

    Dec 1, 2023, 00:00
  • EE492 Economic Analysis and Outcome Research on the Effectiveness of the Return to Work Program on Occupational Injury Cases for Workers with Disabilities

    Dec 1, 2023, 00:00
  • HSD127 Impact of the COVID-19 Pandemic on Frequency of Surgeries in Germany Based on Hospital Data

    Dec 1, 2023, 00:00
  • EE541 Cost-Effectiveness, Health-State Utility Values (HSUVs) and Cost and Resource Use (CRU) Associated with Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS): An Economic Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00
  • PCR243 Psychometric Validation of QlQ-OES18 in 2L Esophageal Squamous Cell Cancer (ESCC) Patients Treated with Tislelizumab Versus Chemotherapy

    Dec 1, 2023, 00:00
  • RWD53 A Real-World Analysis of Treatment Patterns for First-Line Immunotherapies Among Danish Patients with Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression ≥50%

    Dec 1, 2023, 00:00
  • EPH153 Clinical Characterization and Healthcare Resource Utilization in Adrenoleukodystrophy: A Nationwide Retrospective Cohort Using Swedish National Registries

    Dec 1, 2023, 00:00
  • PCR199 Value-Based Healthcare in Severe Asthma: Development of an Outcome Standard Set Pilot Study in Portugal

    Dec 1, 2023, 00:00
  • CO140 Drivers of Physicians’ Treatment Decision-Making and Future Treatment Expectations: Analysis of the Adelphi Real-World Ovarian Cancer II Disease Specific Programme (DSPTM)

    Dec 1, 2023, 00:00
  • EE737 Cost-Effectiveness Models of Continuous Glucose Monitoring in Individuals With Type 1 Diabetes: A Systematic Review on Methodology and Quality

    Dec 1, 2023, 00:00
  • RWD13 Treatment Pathways and Outcomes of Advanced Ovarian Cancer Patients Who Are Underrepresented in Trials

    Dec 1, 2023, 00:00
  • EPH249 Effects of Adolescent MenACWY and MenC Vaccination in Germany: A Modelling Study

    Dec 1, 2023, 00:00
  • PCR112 Characteristics of Individuals Living with Obesity in Germany, Weight-Loss Methods Attempted and Healthcare Resource Use over a 12-Month Period

    Dec 1, 2023, 00:00
  • CO38 Real-World Comparative COVID-19 Vaccine Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 Among Immunocompromised Adults in the US

    Dec 1, 2023, 00:00
  • MT7 Barriers and Facilitators for the Use of Point of Care Diagnostics in Patients With Respiratory Tract Infections in Outpatient Care Related to the Peri-Launch Phase

    Dec 1, 2023, 00:00
  • EPH246 Landscape of Diffuse Large B-Cell Lymphoma (DLBCL) in Brazilian Public Healthcare System (SUS)

    Dec 1, 2023, 00:00
  • RWD110 Lifetime Costs of Stroke in Brazil with a Focus on Hemorrhagic Subtypes

    Dec 1, 2023, 00:00
  • EPH111 A Real-World Study of the Relationship between Lipoprotein(A) [Lp(A)] Concentrations and Atherosclerotic Cardiovascular Disease (ASCVD) Prognosis, Healthcare Resource Utilization and Medical Costs in Chinese Patients

    Dec 1, 2023, 00:00
  • EPH49 The Short-Run and Long-Run Behavioral Effects of Vaccination Enforcement in Turkey

    Dec 1, 2023, 00:00
  • EPH112 Prevalence, Incidence, and Patient Characteristics of Valvular Heart Disease Using the National Database of Health Insurance Claims in Japan

    Dec 1, 2023, 00:00
  • EPH208 Adoption of Precision Health (PH) and Precision Medicine (PM) Approaches in Addressing Population Health Needs in Europe

    Dec 1, 2023, 00:00
  • EE761 The Impact of Differences in Patient Demographics on Assessment of Long-Term Cost-Effectiveness in Cohort Level Economic Models

    Dec 1, 2023, 00:00
  • CO153 Exploring the Impact of Healthcare Provider Stress on Patient Outcomes: A Review Protocol

    Dec 1, 2023, 00:00
  • EE644 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the US

    Dec 1, 2023, 00:00
  • MT79 This Technology Should be Compared With? And Who for? The Digital Health Population Conundrum

    Dec 1, 2023, 00:00
  • HTA153 Did OS Immaturity Preclude from Receiving a Positive Recommendation: Review of Recent Oncology NICE/TA?

    Dec 1, 2023, 00:00
  • HPR87 A Comparative Analysis of Market Access Processes Between Ukraine and Germany

    Dec 1, 2023, 00:00
  • RWD119 A Decade of Alzheimer's Disease Management in Germany: The Increasing Impact of Specialists

    Dec 1, 2023, 00:00
  • EPH11 Prevalence, Risk Factors, and Characterization of Individuals with Long COVID Using Electronic Health Records in Over 1.5 Million COVID Cases in England

    Dec 1, 2023, 00:00
  • EE160 Healthcare Expenditure for Treatment of Hypertension and Hypertensive Complications in Japan: A Claims Data Analysis

    Dec 1, 2023, 00:00
  • HPR151 New Proposed European Commission Pharmaceutical Regulation – Potential Changes and Impact on Biosimilars

    Dec 1, 2023, 00:00
  • CO116 The Significance of Serum Transaminases As Predictors of Mortality in Paraquat Poisoning: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • EPH54 What Do the Students Think About Food Safety Knowledge at the University of Pécs?

    Dec 1, 2023, 00:00
  • HSD76 Assessing the Carbon Intensity Profile of an Immunization Program Against RSV in Infants in the United Kingdom to Show the Reduction in Emissions Versus Standard of Care

    Dec 1, 2023, 00:00
  • HTA120 Trends in Medical Device Reimbursement Decisions in South Korea: A Novel and Comprehensive Analysis

    Dec 1, 2023, 00:00
  • EE318 Cost-Effectiveness Analysis for Soliqua in the Treatment of T2DM in Turkiye

    Dec 1, 2023, 00:00
  • EE237 The Budget Impact of Introducing Automated Hematoxylin and Eosin Staining for Cancer Diagnosis in China

    Dec 1, 2023, 00:00
  • EE74 Cost-Effectiveness Analysis of LUNGFLAGTM Risk Prediction Model in the Selection of Individuals for Lung Cancer Screening in Spain

    Dec 1, 2023, 00:00
  • HTA17 Comparison of Methods for Modelling the Cost-Effectiveness of Atezolizumab as an Adjuvant Treatment in Stage II-IIIA Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00
  • EPH267 A Quinquennial Review of the WHO’s Global Call for Action to Eliminate Cervical Cancer - an Indian Perspective

    Dec 1, 2023, 00:00
  • SA57 Unmet Needs and Evidence Gaps in Relapsed/Refractory Marginal Zone Lymphoma: Findings from a Systematic Literature Review

    Dec 1, 2023, 00:00
  • PCR255 Adherence to Single and Multiple Inhaled Triple Therapies in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, Considering Different Definitions

    Dec 1, 2023, 00:00
  • EE708 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Aclidinium/Formoterol (ACL/FOR) in Patients with COPD in the United Kingdom

    Dec 1, 2023, 00:00
  • HTA84 Is Our Evidence Enough? A Review of G-BA's Ongoing Evidentiary Requirements in the Oncology Space

    Dec 1, 2023, 00:00
  • PT25 Comparison of Approval Dates of New Substances Between the United States of America (Food and Drug Administration, FDA) and Europe (European Medicines Agency, EMA)

    Dec 1, 2023, 00:00
  • MSR56 Incorporating Background Mortality Into Survival Extrapolations: Determining the Accuracy Using a Simulation Study

    Dec 1, 2023, 00:00
  • Adherence to Treatment, Patients' Preferences, and Drug Use across Multiple Diseases

    Dec 1, 2023, 00:00
  • EE453 Projecting the Economic Benefits of the Elective Recovery Plan in England

    Dec 1, 2023, 00:00
  • HTA336 The Danish Health Technology Council – HTA Organisations As the Nexus between Science and Policy

    Dec 1, 2023, 00:00
  • HSD112 Real-World Trends in APOE Genetic Testing Associated with Lecanemab

    Dec 1, 2023, 00:00
  • PCR269 Detecting Changes in Relative Weighting of EQ-5D Dimensions and Levels with Sequential Analytical Hierarchy Process in Hong Kong Sar, China

    Dec 1, 2023, 00:00
  • HSD5 Knowledge, Attitude, and Practice of Pharmacy Professionals Against Dispensing Antibiotics Without Prescription in Ethiopia

    Dec 1, 2023, 00:00
  • HSD113 Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis

    Dec 1, 2023, 00:00
  • Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community [Editor's Choice]

    Dec 1, 2023, 00:00
  • HPR98 Examining Reimbursement and Pricing Decisions of Oncohematological Medicines in Spain

    Dec 1, 2023, 00:00
  • HSD24 Digital Medical Services Delivered by Internet Hospitals via WeChat in China: A Qualitative Analytical Research

    Dec 1, 2023, 00:00
  • EE433 Cost and Duration of Hospital Stays for Complex Patients Receiving a Micra or a Conventional Pacemaker With Epicardial Leads in France

    Dec 1, 2023, 00:00
  • RWD40 Assessing the Representativeness of Body Mass Index Categories Across Multiple Types of Secondary Data Sources

    Dec 1, 2023, 00:00
  • PCR90 Hypoglossal Nerve Stimulation (HGNS) for Obstructive Sleep Apnea (OSA): A Systematic Review and Meta-Analysis of Patient-Reported Outcomes

    Dec 1, 2023, 00:00
  • CO14 Identification Use of Prognostic Variables (PVs)/Treatment Effect Modifiers (TEMs) in Indirect Treatment Comparisons (ITCs) By Systematic Literature Review (SLR): Case Study of Chimeric Antigen Receptor (CAR) T-Cell Therapies

    Dec 1, 2023, 00:00
  • HSD12 Hepatocellular Carcinoma Patient Pathway in Portugal – From Diagnosis to Treatment – Results From Opal Study

    Dec 1, 2023, 00:00
  • HTA347 Exploration of the Factors Driving Decisions of the Transparency Commission Based on an Analysis of HAS Meeting Transcripts Using Natural Language Processing

    Dec 1, 2023, 00:00
  • CO97 Real-World Outcomes in Third-Line and Beyond (3L+) Small-Cell Lung Cancer (SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00
  • HTA151 Subjective Well-Being and Mental Health During the COVID-19 Pandemic in Hungary

    Dec 1, 2023, 00:00
  • PCR117 A Qualitative Interview Study into the Experiences of Fatigue and Depression in Chronic Hepatitis B

    Dec 1, 2023, 00:00
  • HTA107 Are All Unmet Needs Valued the Same? A Review of Disease Prioritization and Related Resource Allocation in Europe

    Dec 1, 2023, 00:00
  • MSR94 Harnessing AI in Health Economics: Enhancing Efficiency, Accuracy, and Decision-Making

    Dec 1, 2023, 00:00
  • EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories

    Dec 1, 2023, 00:00
  • HSD61 The Diagnostic Journey of Patients with Mild Cognitive Impairment and Alzheimer’s Disease Dementia, and the Importance of Biomarker Testing for Timely Diagnosis: A Real-World Survey in Europe

    Dec 1, 2023, 00:00
  • PT20 Applications for Tolvaptan (JINARC®) Under a Managed Access Protocol in Ireland

    Dec 1, 2023, 00:00
  • EE597 Data on Human Population Mobility in Individual-Based Models of Infectious Disease Transmission: A Systematic Review

    Dec 1, 2023, 00:00
  • PCR23 Patient Preferences for Treatment Attributes and Endpoints in Neoadjuvant Therapy for Early-Stage Breast Cancer

    Dec 1, 2023, 00:00
  • SA6 Cost-of-Illness of Skin Cancer: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • RWD180 Analyzing Medical Patterns and Catastrophic Health Expenses in Occupational Injuries Victims in South Korea

    Dec 1, 2023, 00:00
  • HTA197 Increasing Patient Access in Scandinavia Through Outcome Based Agreements: Can the Spanish Model be Replicated?

    Dec 1, 2023, 00:00
  • EE219 Lorlatinib as a First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Greece

    Dec 1, 2023, 00:00
  • HPR116 Is Payment Innovation Keeping Up With Therapy Innovation? A New Taxonomy of Innovative Payment Solutions to Aid Effective Implementation

    Dec 1, 2023, 00:00
  • EE339 Use of Dalbavancin in the Treatment of Pediatric Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis

    Dec 1, 2023, 00:00
  • P26 Drug Utilization, Adherence, and Persistence in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada

    Dec 1, 2023, 00:00
  • EE624 The Economic Burden of Macrovascular Complications of Diabetes in Algeria

    Dec 1, 2023, 00:00
  • CO69 Evidence Gap Analysis of the Burden of Illness and Treatment of Bullous Pemphigoid

    Dec 1, 2023, 00:00
  • EE116 Quantifying the Future Impact of Chronic Kidney Disease Screening Programs in Belgium

    Dec 1, 2023, 00:00
  • HTA314 A Review of Pediatric Medicines Assessed by NICE Between 2018 and 2023

    Dec 1, 2023, 00:00
  • RWD41 Utilization Patterns of Glucagon-like Peptide Receptor Agonists in Patients with Type 2 Diabetes in France and Italy

    Dec 1, 2023, 00:00
  • HTA22 Access to Orphan Pediatric and Adolescent Medicinal Products in Greece Over 4 Years (2018-2021)

    Dec 1, 2023, 00:00
  • HTA267 Is the BBC Truly Impartial When Reporting on NICE’s Activities?

    Dec 1, 2023, 00:00
  • HPR216 Multi-Stakeholder Perspectives on Interpretation, Challenges, and Ways Forward for the Unmet Medical Need Concept – Semi-Structured Interviews

    Dec 1, 2023, 00:00
  • EE268 Healthcare Costs and All-Cause Mortality Following a Hyperkalemia Event and Reduction of RAASi Therapy in Sweden

    Dec 1, 2023, 00:00
  • EE190 How Many Patients Diagnosed with Mild Cognitive Impairment Are Willing to Pay for a PET Scan to Receive the Treatment for Alzheimer′S Disease in Japan?

    Dec 1, 2023, 00:00
  • HPR3 Burden of HIV/AIDS Assessment and Forecast for 2030 in Turkiye

    Dec 1, 2023, 00:00
  • MT24 Digital Therapeutics (DTX): Market Access Challenges and Stakeholder Perspectives in Germany

    Dec 1, 2023, 00:00
  • EE754 Is the Paradigm Shifting? The REvalMED Pilot Program and Subsequent Integration of Economic Evaluations to Influence Pricing and Reimbursement Discussions in Spain

    Dec 1, 2023, 00:00
  • HTA292 Implications of EU HTA on Future Relevance of Surrogate Outcomes in National Assessment

    Dec 1, 2023, 00:00
  • EPH200 Healthcare Resource Consumption of Patients with Chronic Obstructive Pulmonary Disease Treated with Triple and Dual Therapy and Experiencing an Acute Exacerbation

    Dec 1, 2023, 00:00
  • CO10 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Psoriatic Arthritis

    Dec 1, 2023, 00:00
  • EE106 Artificial Intelligence (AI) Based Telemedicine for Cost-Effective Cataract Surgery Follow-up at NHS: An Economic Evaluation

    Dec 1, 2023, 00:00
  • EE223 Estimation of the T-Cell Engagers (Bi-Specific Monoclonal Antibodies and Chimeric Antigen Receptor [CAR T-CELL]) Therapy Administration Pathways From French Hospitals and National Health Insurance Perspective and Financial Impact

    Dec 1, 2023, 00:00
  • EE263 Economic and Healthcare Burden of Blood Transfusions in Transfusion-Dependent Beta-Thalassemia in Thailand and Brazil

    Dec 1, 2023, 00:00
  • HPR41 Linking the Price of a Drug to Its Real-Life Performan A Solution for Financing Innovative Therapies in France?

    Dec 1, 2023, 00:00
  • HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis

    Dec 1, 2023, 00:00
  • EE85 Health System Costs and Resources for Stage-Specific Breast Cancer: A Population-Based Approach (Updated)

    Dec 1, 2023, 00:00
  • HTA91 5 Years of CAR-T Cell Therapies—Comparison of German AMNOG Dossiers in Terms of Available Evidence and Price Development

    Dec 1, 2023, 00:00
  • P19 Demographics of Patients and Societal Burden of Obstructive Hypertrophic Cardiomyopathy: Results From a Real-World Survey in Italy and Spain

    Dec 1, 2023, 00:00
  • RWD57 Treatment Patterns and Cost of Care Among Patients With Metachromatic Leukodystrophy (MLD) in the US

    Dec 1, 2023, 00:00
  • HTA284 Early Access in Fran Descriptive Analysis of Eap Decisions Two Years after the Reform

    Dec 1, 2023, 00:00
  • HTA281 Environmental Considerations in HTA: Can HTA Bodies Contribute to Environmental Sustainability?

    Dec 1, 2023, 00:00
  • EE249 Cost and Outcomes of Teduglutide in Adult Patients With Short Bowel Syndrome—Is the Combination With BSC Cost-Effective for the Society?

    Dec 1, 2023, 00:00
  • EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations

    Dec 1, 2023, 00:00
  • EPH107 Predictors and Consequences of Pediatric Nurses' Burnout: An Integrative Review

    Dec 1, 2023, 00:00
  • MSR42 A Parametric Method for Unanchored Matching-Adjusted Indirect Treatment Comparison (MAIC) Based on Survival Outcomes for Health Economic (HE) Models in Absence of Proportional Hazards (PH)

    Dec 1, 2023, 00:00
  • EE234 Economic Analysis of the Pronto Study

    Dec 1, 2023, 00:00
  • EE367 The Use of Genomic Tests for Early Breast Cancer in Finland Is Likely to be Cost-Effective at Common WTP Threshold

    Dec 1, 2023, 00:00
  • MSR149 Cost-Effectiveness Model Conceptualisation in Chronic Graft Versus Host Disease

    Dec 1, 2023, 00:00
  • MT28 Physician Experiences and Preferences in Peripheral Bronchoscopy for Diagnosing Patients with Solitary Pulmonary Nodules Suspected of Lung Cancer: A Multi-Country, Cross-Sectional Survey

    Dec 1, 2023, 00:00
  • HSD73 Establishing a Learning Healthcare System for Metastatic Prostate Cancer in the Dutch Healthcare System: Preconditions and Potential Benefits of Real-World Data Utilization

    Dec 1, 2023, 00:00
  • EE144 Decision Modifiers Under Uncertainty: Comparison of Deterministic and Probabilistic Methods in Disease Severity Classification by NICE

    Dec 1, 2023, 00:00
  • HTA251 Unraveling the Relationship between Expedited Regulatory Approval By the European Medicines Agency (EMA) and Reimbursement Outcomes for Drugs Approved Under Exceptional Circumstances

    Dec 1, 2023, 00:00
  • EE615 A Cost-Effectiveness Analysis of the CNIC-Polypill Strategy, Compared to Usual Care, in Secondary Cardiovascular Prevention from a Spanish Perspective Using Data from the Secure Trial

    Dec 1, 2023, 00:00
  • HSD45 Atopic Dermatitis’ Treatment Patterns in Latin America: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • PCR60 Shared Decision Making in Inflammatory Bowel Disease Clinical Practi What Are the Experiences, Barriers, and Opportunities According to Patients and Healthcare Professionals?

    Dec 1, 2023, 00:00
  • EE429 Current Parallel Trade Practice in the Pharmaceutical Industry Focusing on European Single Market, Utilizing a Cost-Saving Analysis in the Allergen Immunotherapy Market of Germany

    Dec 1, 2023, 00:00
  • HPR63 Plasma Last Liter Economics and Its Impact on the Costs of Major Human Polyvalent Immunoglobulins in Europe

    Dec 1, 2023, 00:00
  • HTA226 Can Prior Indirect Treatment Comparisons (ITCs) Inform Health Technology Assessment (HTA) Strategy: A Case Study in Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)

    Dec 1, 2023, 00:00
  • P39 Machine Learning to Identify Atopic Dermatitis Prevalence Using Healthcare Utilisation Patterns of Both Diagnosed and Non-Diagnosed AD Patients Based on Danish Register Data

    Dec 1, 2023, 00:00
  • PCR208 Pace CKD Financial Burden and Work Productivity Assessment of Chronic Kidney Disease on Patients: Results from an International Survey

    Dec 1, 2023, 00:00
  • EE655 Patients Level Cost of Treating Adverse Events in Alzheimer’s Disease for US-FDA Approved Treatments

    Dec 1, 2023, 00:00
  • PCR264 Impact of Sodium Glucose Cotransporter-2 Inhibitors (SGLT2is) on Health-Related Quality of Life (HRQoL) Outcomes in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2023, 00:00
  • HTA81 Exploring the Gap Between Regulatory Labels and Reimbursed Indications of Oncology Drugs in the Netherlands

    Dec 1, 2023, 00:00
  • HSD23 Health Technology Management - The Future of the Post-Reimbursement Phase?

    Dec 1, 2023, 00:00
  • RWD23 Comparison of the Use of Real-World Evidence (RWE) by Health Technology Assessment (HTA) Agencies in Reviews of Drugs for Rare Diseases (DRDS)

    Dec 1, 2023, 00:00
  • SA43 Methods of Estimating Annualized Bleed Rates from Medical Records Among Patients with Hemophilia A

    Dec 1, 2023, 00:00
  • EPH114 Clinical Characteristics, Average Cost Per Visit, and Major Adverse Cardiovascular Events in Patients with Diagnosed Chronic Kidney Disease Combined with Cardiovascular Disease: A Study from a Large Healthcare Database in China

    Dec 1, 2023, 00:00
  • EE96 Resource Consumption Analysis in Patients with Hemophilia A Without Inhibitors on Prophylaxis with FVIII Before Switching to Emicizumab

    Dec 1, 2023, 00:00
  • EE466 Economic Evaluation of Improving Medication Adherences for Secondary Cardiovascular Disease Prevention: A Threshold Analysis

    Dec 1, 2023, 00:00
  • EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient

    Dec 1, 2023, 00:00
  • RWD48 Identification and Assessment of Real-World Oncology Data in China: A Data Landscaping Study

    Dec 1, 2023, 00:00
  • MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias

    Dec 1, 2023, 00:00
  • EE476 Cost Analysis of Patiromer Versus Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia in the UK, Italy and Spain

    Dec 1, 2023, 00:00
  • EE133 Potential Budget Impact of Negative Pressure Wound Therapy (NPWT) Versus Conventional Wound Treatment (CWT) in Diabetic Foot Ulcers (DFU), Surgical Abdominal Wounds with Healing Impairment (SAWHI), and Trauma Wounds for Mexico

    Dec 1, 2023, 00:00
  • EE157 The Societal Impact of Inclisiran Using Population Health Approaches Across 15 Countries

    Dec 1, 2023, 00:00
  • EPH73 Modelling the Wider Socio-Economic Costs of Problematic Opioid Use in Germany

    Dec 1, 2023, 00:00
  • The Impact of Cost-Containment Initiatives from across the Globe

    Dec 1, 2023, 00:00
  • EPH256 Healthcare Resource Utilization and Related Cost Among Patients Hospitalized for Prurigo Nodularis: A Retrospective Cohort Study Using Italian Health Claims Data

    Dec 1, 2023, 00:00
  • EE252 The Economic Implication of Sinus Rapid Relief Pathway in Italy: Awake Surgery Vs General Anesthesia to Guarantee Quick Access to Patients Who Needs Sinus Surgery

    Dec 1, 2023, 00:00
  • EE532 A Conceptual Model for the Cost Effectiveness of Artificial Intelligence-Assisted Chest Computed Tomography (CT) to Detect Lung Nodules and Improve Decision Making

    Dec 1, 2023, 00:00
  • EE638 Cost-Effectiveness of Vasopressin Alone or in Combination With SOC in the Treatment of Sepsis and Septic Shock Patients

    Dec 1, 2023, 00:00
  • MSR66 Natural Language Processing to Support the Abstract Selection During Systematic Literature Review

    Dec 1, 2023, 00:00
  • EPH18 Incidence of Postpartum Mental and Behavioral Disorders in Japan

    Dec 1, 2023, 00:00
  • EE311 Starts with Sacubitril/Valsartan in the Inpatient Vs Outpatient Setting in Spain

    Dec 1, 2023, 00:00
  • HTA200 Review of Population-Adjusted Indirect Treatment Comparison Methods in NICE Non-Oncology Appraisals

    Dec 1, 2023, 00:00
  • PCR80 Patient Preferences for Stages II/III and Stage IV Melanoma Treatments in the UK

    Dec 1, 2023, 00:00
  • EE589 Use of Copulas for Correlated Sampling of Cost and Utility Parameters During Probabilistic Sensitivity Analysis for Cost-Effectiveness Analyses

    Dec 1, 2023, 00:00
  • HTA145 Similarity of Guidelines for Direct and Indirect Comparisons Under Eunethta and Country-Specific HTA – Implications for Supportive Agents

    Dec 1, 2023, 00:00
  • EE669 Quality of Life and Economic Burden of Advanced Non-Small Cell Lung Cancer in Medium and Small Markets (MEDSM): A Systematic Literature Review

    Dec 1, 2023, 00:00
  • EPH88 Human Papillomavirus (HPV) Vaccination Coverage Among French Adolescents: Papillon Study

    Dec 1, 2023, 00:00
  • HTA218 Public Engagement and Its Influence on Health Technology Assessment Outcomes in Latin America

    Dec 1, 2023, 00:00
  • MSR92 Can Artificial Intelligence (AI) Large Language Models (LLMS) Such as Generative Pre-Trained Transformer (GPT) Be Used to Automate Literature Reviews?

    Dec 1, 2023, 00:00
  • EE271 Cost-Effectiveness of Finerenone in Addition to Standard-of-Care in Treating Type 2 Diabetes and Chronic Kidney Disease in China

    Dec 1, 2023, 00:00
  • HTA230 Comparative Evaluation of the Performance of Two Value Attribution Frameworks When Applied to Combination Regimens in Oncology

    Dec 1, 2023, 00:00
  • MT68 Digital Therapeutics (DTx) for Alzheimer's Disease, Dementia and Mild Cognitive Impairment: A Pragmatic Review of Clinical Evidence

    Dec 1, 2023, 00:00
  • PCR274 Patient Data Use in Medical Research Vs Data Privacy: Perspective from Five Patient Association Representatives

    Dec 1, 2023, 00:00
  • HTA257 Key HTA Learnings from Approved Gene Therapies Across the EU4, England, and the US

    Dec 1, 2023, 00:00
  • PCR9 Rise of Undiagnosed Major Depressive Disorder Post-COVID-19 Pandemic in Europe

    Dec 1, 2023, 00:00
  • RWD61 Inclusion of Productivity Losses and Gains in Cost-Effectiveness Analyses in Psoriasis: Preliminary Report of a Brazilian Association of Psoriasis (LATAM/LMIC)

    Dec 1, 2023, 00:00
  • EPH7 Estimating the Projected Impact of Weight Loss on Obesity Prevalence and Healthcare Costs in a UK Population

    Dec 1, 2023, 00:00
  • HPR144 Support of RWE in the Price and Reimbursement Decision-Making Process for Rare Diseases in Spain

    Dec 1, 2023, 00:00
  • HTA300 How Fast Will the EU HTA Child Grow? Estimation of the Number of Procedures in the First Years of Implementation

    Dec 1, 2023, 00:00
  • SA8 The Use of Care Pathway Analysis to Inform Health Economic Models and Evidence Generation Requirements: Practical Applications and Examples from Two Projects

    Dec 1, 2023, 00:00
  • MSR63 Implementing Simple Active Learning (AL) Boosters Considerably Improves the Early Identification of Relevant Studies in the Systematic Literature Review (SLR) Process

    Dec 1, 2023, 00:00
  • HTA92 A Targeted Review of Methods for Effect Modifier (EM) and Prognostic Factor Identification in Population Adjusted Indirect Comparisons (PAICs) in NICE Oncology Submissions

    Dec 1, 2023, 00:00
  • EE395 Economic Burden and Cost Drivers of Dystrophic Epidermolysis Bullosa: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • PCR82 Hierarchical Clustering of Rare Diseases Based on Functional Impacts to Support the Identification of Potential Patient-Centered Outcomes Measures for Rare Diseases Research

    Dec 1, 2023, 00:00
  • CO6 Teduglutide for Treating Short-Bowel Syndrome in Adults: A Meta-Analysis of Real-World Evidence Compared to Clinical Trial Data

    Dec 1, 2023, 00:00
  • EPH137 Healthcare Resource Consumption and Direct Costs of Patients Newly Diagnosed with Acute Myeloid Leukemia from a Large Italian Administrative Database

    Dec 1, 2023, 00:00
  • MSR121 Use of External Control Arms in Pharmaceutical Submissions to the National Institute for Health and Care Excellence for Technology Appraisals: A Targeted Review

    Dec 1, 2023, 00:00
  • HTA3 Health Technology Assessment Requirements: Sensitive to Bacteriophage Products or Too Resistant to Change?

    Dec 1, 2023, 00:00
  • Cover

    Dec 1, 2023, 00:00
  • RWD158 Estimates on Waste of Breast Cancer Related Chemotherapy Drugs in the NHS (ENGLAND)

    Dec 1, 2023, 00:00
  • PCR44 Work and Activity Impairment in Individuals With Chronic Kidney Disease According to Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Use

    Dec 1, 2023, 00:00
  • EE722 Cost-Utility Analysis for Haemate-P in the Treatment of Von Willebrand Disease

    Dec 1, 2023, 00:00
  • HTA334 Assessment of Vaccines in Europe, the HPV Example: Can the EU Joint Clinical HTA Regulation Result in More Consistent Vaccine Evaluations and Improve Access Across EU Countries?

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22
  • 23
  • 24
  • 25 (current)
  • 26
  • 27
  • 28
  • 29
  • 30
  • »